Evidence map›Paper›PMID 41639975›Full record

Trial reportEuropean heart journal. Cardiovascular Imaging2026

Additive prognostic value of functional performance to coronary artery anatomy: the ISCHEMIA trial.

Sagit Ben Zekry, Georgios Tzimas, Jonathon Leipsic, Samuel Broderick, G B John Mancini, Cameron J Hague, Matthew J Budoff, James K Min, Bernard R Chaitman, Frank W Rockhold and 13 more

Abstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in European heart journal. Cardiovascular Imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Sagit Ben ZekryNon-invasive Cardiology Unit, Leviev Heart Center, Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel.
Georgios TzimasDepartment of Medicine and Radiology, University of British Columbia, Vancouver, St. Paul's Hospital, 1081 Burrard Street Vancouver, BC, V6Z 1Y6, Canada.ORCID 0000-0002-2810-8887
Jonathon LeipsicDepartment of Medicine and Radiology, University of British Columbia, Vancouver, St. Paul's Hospital, 1081 Burrard Street Vancouver, BC, V6Z 1Y6, Canada.ORCID 0009-0002-3892-9029
Samuel BroderickDuke Clinical Research Institute, Durham, NC, USA.
G B John ManciniDepartment of Medicine and Radiology, University of British Columbia, Vancouver, St. Paul's Hospital, 1081 Burrard Street Vancouver, BC, V6Z 1Y6, Canada.
Cameron J HagueDepartment of Medicine and Radiology, University of British Columbia, Vancouver, St. Paul's Hospital, 1081 Burrard Street Vancouver, BC, V6Z 1Y6, Canada.
Matthew J BudoffDepartment of Medicine and Division of Cardiology, Lundquist Institute, Los Angeles, CA, USA.
James K MinCleerly Inc., New York, NY, USA.
Bernard R ChaitmanSt. Louis University School of Medicine, Center for Comprehensive Cardiovascular Care, St. Louis, MO, USA.ORCID 0000-0002-9216-5317
Frank W RockholdDuke Clinical Research Institute, Durham, NC, USA.
Derek CyrDuke Clinical Research Institute, Durham, NC, USA.
Leslee J ShawDivision of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Daniel S BermanDepartments of Imaging and Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Michael H PicardDepartment of Medicine, Cardiovascular Division, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-9264-3243
Daniel B MarkDuke Clinical Research Institute, Durham, NC, USA.ORCID 0000-0001-6340-8087
Jerome L FlegNational Heart Lung and Blood Institute, Bethesda, MD, USA.
Kian Keong PohNational University Heart Center Singapore, Singapore, Singapore.
Ziad A AliDepartment of Cardiology, St. Francis Hospital, New York, NY, USA.
Gregg W StoneDivision of Cardiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-3416-8210
Sean M O'BrienDuke Clinical Research Institute, Durham, NC, USA.
Judith S HochmanLeon H. Charney Division of Cardiology, Department of Medicine, Cardiovascular Clinical Research Center, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-5889-5981
David J MaronDepartment of Medicine, Stanford University, Stanford, CA, USA.ORCID 0000-0002-4867-8588
Harmony R ReynoldsLeon H. Charney Division of Cardiology, Department of Medicine, Cardiovascular Clinical Research Center, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0003-0284-0655

Funding

The Ischemia Trial - CCCU01HL105907 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HOCHMAN, JUDITH S · 2011 to 2019
$100.1M
The ISCHEMIA Trial - SDCCU01HL105462 · NHLBI · DUKE UNIVERSITY · PI ALEXANDER, KAREN P, O'BRIEN, SEAN M · 2011 to 2019
$17.8M
THE ISCHEMIA TRIAL - IICCU01HL105561 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SHAW, LESLEE J · 2011 to 2018
$6.5M
The ISCHEMIA Trial - EQOLU01HL105565 · NHLBI · DUKE UNIVERSITY · PI MARK, DANIEL B · 2011 to 2017
$2.4M
HHSNCATS NIH HHSNHLBI NIH HHSNHLBI NIH HHS U01 HL105462NHLBI NIH HHS U01 HL105561NHLBI NIH HHS U01 HL105565NHLBI NIH HHS U01 HL105907
6 · The paper itself

Abstract

aimsTo assess whether baseline functional performance assessed by exercise treadmill stress testing (EST) has additive value to coronary computed tomography angiography (CCTA) for risk stratification among patients with chronic coronary disease (CCD) and moderate or severe ischaemia. METHODS AND

resultsWe performed a subgroup analysis of the ISCHEMIA trial including participants who underwent EST and CCTA. EST data and severity of coronary artery disease (CAD) on CCTA were evaluated by core laboratories, blinded to clinical data and results of the other tests. The primary outcome for this analysis was all-cause death. Secondary outcomes were cardiovascular death, cardiovascular death or myocardial infarction (MI), MI and a composite of cardiovascular death, MI, or hospitalization for heart failure, unstable angina, or resuscitated cardiac arrest. EST and the number of vessels diseased on CCTA were both interpretable in 1864 patients (median age 62 years, IQR 55-68, 83% males). During a median follow-up of 3.1 years, 69 patients died. Higher peak metabolic equivalents (METs) achieved on the qualifying stress test was associated with lower all-cause death (HR 0.86, 95% CI 0.76-0.98; P = 0.025). The addition of peak METs to CAD severity improved the predictive ability of the all-cause death and CV death models by 10-20% and 8-13% respectively, depending on the metrics used for CCTA. Adding peak METs to CCTA anatomical models resulted in better prediction of MI by 11-17%, cardiovascular death or MI by 10-14%, and 5-component composite outcome by 12-16%.

conclusionPeak METs on EST, a marker of functional performance, added prognostic value to models including CCTA anatomical findings in patients with CCD and moderate or severe ischaemia.

Indexed as

Computed Tomography AngiographyCoronary AngiographyCoronary Artery DiseaseExercise TestAgedCause of DeathFemaleHumansMaleMiddle AgedPredictive Value of TestsPrognosisRisk AssessmentSeverity of Illness IndexCCTACoronary artery diseaseExercise capacityISCHEMIA trialPrognosisStress testing

Identifiers

PMID41639975
PMCPMC13014304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.